Zscaler: A Cloud Security Contender At An Attractive Entry Point

ZS is positioned to benefit from secular zero-trust security adoption, boasting 23%+ revenue growth, ~32% FCF margins, and a ...
Le Lézard

itSynergy Announces Expanded Cybersecurity and Compliance Services for Registered Investment Advisers

PHOENIX, AZ / ACCESS Newswire / May 15, 2026 / In an environment where cybersecurity examinations are no longer occasional events but an expected part of regulatory oversight, Registered Investment ...

Fortress Biotech, Inc.: Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

ZYCUBO approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 milli ...
ITWeb Africa

When prevention fails, recovery leads cyber defense

Digital disruption is now almost inevitable, so the ability to recover quickly is becoming the defining characteristic of ...
Homeland Security Today

Free Cybersecurity Playbook Offers Small and Mid-Sized Businesses 10 Low-Cost Ways to Strengthen Defenses

Small and medium-sized businesses are increasingly becoming targets for cybercriminals, even as many continue operating ...
The Manila Times

UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced UGN-103 achieved a 94.5% (95% CI: 86.1, 97.9) ...